180 related articles for article (PubMed ID: 27012422)
1. L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells.
Jung SA; Lee DH; Moon JH; Hong SW; Shin JS; Hwang IY; Shin YJ; Kim JH; Gong EY; Kim SM; Lee EY; Lee S; Kim JE; Kim KP; Hong YS; Lee JS; Jin DH; Kim T; Lee WJ
Free Radic Biol Med; 2016 Jun; 95():200-8. PubMed ID: 27012422
[TBL] [Abstract][Full Text] [Related]
2. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
[TBL] [Abstract][Full Text] [Related]
3. Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer.
Aguilera O; Muñoz-Sagastibelza M; Torrejón B; Borrero-Palacios A; Del Puerto-Nevado L; Martínez-Useros J; Rodriguez-Remirez M; Zazo S; García E; Fraga M; Rojo F; García-Foncillas J
Oncotarget; 2016 Jul; 7(30):47954-47965. PubMed ID: 27323830
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS
Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098
[TBL] [Abstract][Full Text] [Related]
5. SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment.
Hong SW; Lee SH; Moon JH; Hwang JJ; Kim DE; Ko E; Kim HS; Cho IJ; Kang JS; Kim DJ; Kim JE; Shin JS; Jung DJ; Jeong YJ; Cho BJ; Kim TW; Lee JS; Kang JS; Hwang YI; Noh DY; Jin DH; Lee WJ
Oncogene; 2013 Mar; 32(12):1508-17. PubMed ID: 22665050
[TBL] [Abstract][Full Text] [Related]
6. Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer.
Park HJ; Park JB; Lee SJ; Song M
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28800074
[TBL] [Abstract][Full Text] [Related]
7. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
8. The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.
Allen JE; Gallant JN; Dicker DT; Amin S; Irby RB; Sharma AK; El-Deiry WS
PLoS One; 2013; 8(3):e59380. PubMed ID: 23555026
[TBL] [Abstract][Full Text] [Related]
9. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
[TBL] [Abstract][Full Text] [Related]
10. SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts.
Wang C; Lv H; Yang W; Li T; Fang T; Lv G; Han Q; Dong L; Jiang T; Jiang B; Yang G; Wang H
Cancer Lett; 2017 Jul; 398():1-11. PubMed ID: 28385602
[TBL] [Abstract][Full Text] [Related]
11. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
12. Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic
Cenigaonandia-Campillo A; Serna-Blasco R; Gómez-Ocabo L; Solanes-Casado S; Baños-Herraiz N; Puerto-Nevado LD; Cañas JA; Aceñero MJ; García-Foncillas J; Aguilera Ó
Theranostics; 2021; 11(8):3595-3606. PubMed ID: 33664850
[No Abstract] [Full Text] [Related]
13. Hormetic dose response to
Cho S; Chae JS; Shin H; Shin Y; Song H; Kim Y; Yoo BC; Roh K; Cho S; Kil EJ; Byun HS; Cho SH; Park S; Lee S; Yeom CH
Sci Rep; 2018 Jul; 8(1):11372. PubMed ID: 30054560
[No Abstract] [Full Text] [Related]
14. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
[TBL] [Abstract][Full Text] [Related]
15. A combinatorial strategy for treating KRAS-mutant lung cancer.
Manchado E; Weissmueller S; Morris JP; Chen CC; Wullenkord R; Lujambio A; de Stanchina E; Poirier JT; Gainor JF; Corcoran RB; Engelman JA; Rudin CM; Rosen N; Lowe SW
Nature; 2016 Jun; 534(7609):647-51. PubMed ID: 27338794
[TBL] [Abstract][Full Text] [Related]
16. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
17. Digitoxin promotes apoptosis and inhibits proliferation and migration by reducing HIF-1α and STAT3 in KRAS mutant human colon cancer cells.
Mi C; Cao X; Ma K; Wei M; Xu W; Lin Y; Zhang J; Wang TY
Chem Biol Interact; 2022 Jan; 351():109729. PubMed ID: 34717917
[TBL] [Abstract][Full Text] [Related]
18. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
[TBL] [Abstract][Full Text] [Related]
19. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
Chattopadhyay N; Berger AJ; Koenig E; Bannerman B; Garnsey J; Bernard H; Hales P; Maldonado Lopez A; Yang Y; Donelan J; Jordan K; Tirrell S; Stringer B; Xia C; Hather G; Galvin K; Manfredi M; Rhodes N; Amidon B
PLoS One; 2015; 10(12):e0144825. PubMed ID: 26709701
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS.
Ishida T; Ishii Y; Tsuruta M; Okabayashi K; Akimoto S; Koishikawa K; Hasegawa H; Kitagawa Y
Oncol Rep; 2017 Aug; 38(2):926-932. PubMed ID: 28656305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
